Eli Lilly (LLY)

There are new ways to tackle weight loss, but the stocks leading the way are lagging.

Chinese suppliers of semaglutide and tirzepatide that fueled a U.S. weight-loss drug boom are pivoting to generics as FDA crackdowns.

A 57% risk reduction for heart attacks and strokes sounds like an amazing result.

The specter of persistent inflation continues to loom large over the U.S. economy, keeping both consumers and policymakers on edge. Despite the Federal Reserve's aggressive campaign of interest rate hikes, the Personal Consumption Expenditures (PCE) price index, the central bank's preferred gauge of inflation, continues to run above its

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.

Novo Nordisk's Wegovy cut cardiovascular risks significantly versus tirzepatide in a real-world study, showing fewer heart attacks, strokes, and deaths.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Elanco (NYSE:ELAN) and the best and worst performers in the pharmaceuticals industry.

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

This could put pressure on Eli Lilly, which sells a competing drug called Kisunla.

A significant sector rotation is currently underway in equity markets, shifting investor capital away from the mega-cap technology stocks that dominated recent years towards more traditional value and cyclical segments. This trend, gaining significant momentum in 2025, sees sectors such as financial services, basic materials, healthcare, energy, and industrials outperforming,

Novo Nordisk alone contributing one-fifth of employment gains to Denmark. But economic headwinds are mounting.

The FDA now requires earlier MRI screening for Alzheimer's drug Leqembi to detect ARIA-E, a rare but serious side effect, aiming to improve treatment safety for patients.

Here's why investors aren't sure what to make of Nvidia earnings.

Investment bank analysts up and down Wall Street are pounding the table on these stocks.

The U.S. economy currently navigates an intriguing, yet precarious, path as hypothetical Q2 2025 data suggests a robust rebound in Gross Domestic Product (GDP) growth. This economic buoyancy, however, is shadowed by the persistent specter of inflation, with the Personal Consumption Expenditures (PCE) price index stubbornly holding above the

Shares of Eli Lilly (LLY) are testing a resistance level. If they can break through this resistance, a large more higher may follow.

Prothena reported ASCENT trial data showing strong amyloid plaque reduction but high ARIA-E rates for Alzheimer's drug PRX012, prompting a shift in focus.

The global economic landscape remains deeply entrenched in a complex and often volatile trade conflict between the United States and China. What began in January 2018 as a series of targeted duties has escalated significantly through 2025, with both nations frequently adjusting and reinstating tariffs, creating a tangled web of

Novo Nordisk has entered into a collaboration with Replicate BioScience under which it will receive a defined, exclusive, worldwide license to use the latter’s self-replicating RNA platform to develop and commercialize treatments.

These two longtime market leaders should continue to perform well.

Investors looking for top growth stocks on the Nasdaq and NYSE may want to consider alternatives to the Invesco QQQ.

Novo Nordisk stock remains under pressure this year. But the company is now launching Wegovy in MASH treatment.